Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, Ph.D., recently joined the Company and will serve as Senior Vice President of Regulatory Affairs.

“The high caliber of individuals, including both Martha and Amy, who have joined Achillion in recent months highlights the excitement for Achillion’s factor D inhibitor program and the potential for our small molecule compounds to address the unmet needs of patients with ultra-rare diseases,” commented Milind Deshpande, Ph.D., President and Chief Executive Officer. “I am pleased to welcome Martha, who joins us with more than two decades of industry experience at pharmaceutical companies both large and small, and Amy, who most recently was the head of U.S. regulatory for diabetes at Sanofi. I believe that their addition to the Achillion team further enhances our goal of maturing into a commercial pharmaceutical company.”

Martha E. Manning, Esq.

Martha E. Manning, Esq. joined Achillion in February 2016 as General Counsel. Previously, she was General Counsel of iCeutica Inc., a drug development company from 2013 to 2016. She served as Chief Legal Officer of OraPharma, Inc., a J&J spinout company, from 2011 to 2012 when the Company was acquired by Valeant. She joined OraPharma from Sandoz Inc., the generic pharmaceutical division of Novartis, where she served as Vice President and General Counsel from 2008 to 2011. Prior to Sandoz, she served as Senior Vice President, General Counsel and Secretary for Adolor Corporation, a publicly traded biopharmaceutical company from 2002 to 2008. Martha began her legal career with the law firm of Morgan, Lewis & Bockius. She received her J.D. from the University of Pennsylvania School of Law and her Bachelor of Business Administration from the University of Massachusetts.

Amy Jennings, Ph.D.

Amy Jennings joined Achillion in January 2016 and serves as Senior Vice President of Regulatory Affairs. She was previously with Sanofi where she was the head of US regulatory for diabetes. Prior to Sanofi, Amy assumed roles of increasing responsibility at Bristol-Myers Squibb within Regulatory over more than 12 years, culminating in her leading U.S. regulatory for CV/Metabolics. During her tenure at BMS, she was involved with both U.S. and Global regulatory for all phases of drug development, across broad therapeutic areas, and contributed to multiple drug approvals, including leading the U.S. regulatory efforts for the recent approvals of Farxiga and Xigduo XR for patients with type 2 diabetes. To obtain the U.S. approval of Farxiga, Amy led the team through the NDA submission, preparation of two advisory committee meetings, and an NDA resubmission.

Amy earned a BS in Chemistry from the University of Wisconsin-Madison and a Ph.D. in Biochemistry from The Ohio State University. She was a post-doctoral fellow at the Joslin Diabetes Center prior to joining the pharmaceutical industry. (Original Source)

Shares of Achillion Pharmaceuticals closed yesterday at $6.41. ACHN has a 1-year high of $13.08 and a 1-year low of $6.21. The stock’s 50-day moving average is $8.74 and its 200-day moving average is $8.49.

On the ratings front, Leerink Swann analyst Howard Liang downgraded ACHN to Hold, in a report issued on January 29. According to, Liang has a total average return of 19.7%, a 54.8% success rate, and is ranked #115 out of 3600 analysts.

Achillion Pharmaceuticals Inc is a biopharmaceutical company which focuses on the discovery, development and commercialization of treatments for infectious diseases like hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free.